CSIMarket
 

Puma Biotechnology Inc   (NASDAQ: PBYI)

Puma Biotechnology Inc 's

Competitiveness




 

PBYI Sales vs. its Competitors Q2 2026



Comparing the current results to its competitors, Puma Biotechnology Inc reported Revenue increase in the 2 quarter 2026 by 7.75 % year on year.
The revenue growth was below Puma Biotechnology Inc 's competitors' average revenue growth of 12.84 %, achieved in the same quarter.

• List of PBYI Competitors

With a net margin of 14.49 % Puma Biotechnology Inc achieved higher profitability than its competitors.

• More on PBYI Profitability Comparisons



Revenue Growth Comparisons




Net Income Comparison


Puma Biotechnology Inc Net Income in the 2 quarter 2026 grew year on year by 39.86%, while most of its competitors have experienced a contraction in net income by -6.69 %.

<<  PBYI Stock Performance Comparisons


Puma Biotechnology Inc 's Comment on Competition and Industry Peers


The company operates in a competitive cancer treatment market alongside major pharmaceutical, biotechnology, and specialty cancer firms. Competitors include Genentech, Novartis, Roche, Boehringer Ingelheim, Lilly, Merck, AbbVie, Pfizer, Amgen, Daiichi Sankyo, Jazz, and Seagen. Merck, AbbVie, Amgen, Daiichi Sankyo, and Jazz are developing drugs for small cell lung cancer, while the others focus on early-stage and metastatic HER2-positive breast cancer or related cancer types. The company notes that many competitors possess greater financial resources and expertise in drug development and commercialization. Industry mergers and acquisitions may further consolidate resources among fewer competitors. Smaller or early-stage companies may also present competition, particularly through collaborations with larger firms. Competition extends to recruiting qualified personnel, establishing clinical trial sites, enrolling subjects, and acquiring complementary technologies.



  

Overall company Market Share Q2 2026

Revenue in Overall company grew by 7.75 %, less than Puma Biotechnology Inc peers within this division.
<<  More on PBYI Market Share.
 
*Market share is calculated based on total revenue.

  News about Puma Biotechnology Inc Contracts

In an era where biopharmaceutical companies are pivotal in developing innovative therapies...

February 27, 2025
for CSIMarket.com : Comparative Financial Performance and Market Positioning of Puma Biotechnology Inc. In an era where biopharmaceutical companies are pivotal in developing innovative therapies, Puma Biotechnology Inc. (NASDAQ: PBYI) has demonstrated ...





Publicly Traded Peers of Puma Biotechnology Inc




Aquestive Therapeutics Inc
Share Performance



-13.17%
30 Days



Aquestive Therapeutics Inc
Profile

Aquestive Therapeutics Inc follows a business model that focuses on the development and commercialization of innovative products to address unmet medical needs. The company primarily operates in the pharmaceutical industry, leveraging its proprietary drug delivery technology to create and improve various medications for patients.

More about Aquestive Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 584.973 mill. $ 54.087 mill. $ -78.227 mill.


Immunoprecise Antibodies Ltd
Share Performance



+3.50%
30 Days



Immunoprecise Antibodies Ltd
Profile

Immunoprecise Antibodies Ltd operates as a contract research organization specializing in the discovery and development of therapeutic antibodies to advance the treatment of various diseases. Through customized antibody solutions and a comprehensive portfolio of services, they offer support to pharmaceutical and biotechnology companies to accelerate their drug development processes.

More about Immunoprecise Antibodies Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 96.287 mill. $ 20.186 mill. $ -9.057 mill.


Biomarin Pharmaceutical Inc
Share Performance



+5.11%
This Quarter



Biomarin Pharmaceutical Inc
Profile

Biomarin Pharmaceutical Inc operates as a biotechnology company, specializing in the development and commercialization of innovative therapies for rare genetic diseases. Their business model revolves around conducting extensive research and development to identify and address unmet medical needs, manufacturing and marketing their approved products, and collaborating with strategic partners to maximize the reach and impact of their therapies worldwide. By focusing on rare diseases, Biomarin leverages their expertise to provide targeted and innovative treatments, ultimately improving the lives of patients in need.

More about Biomarin Pharmaceutical Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 11,718.581 mill. $ 3,406.614 mill. $ 72.972 mill.


Opko Health Inc
Share Performance



+8.61%
30 Days



Opko Health Inc
Profile

Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.

More about Opko Health Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,238.638 mill. $ 587.896 mill. $ -72.890 mill.


Allarity Therapeutics Inc
Share Performance



-14.88%
Over The Past 5 Days



Allarity Therapeutics Inc
Profile

Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.

More about Allarity Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 16.388 mill. $ - mill. $ -12.334 mill.

196 more competitors available

Sign in to see all competitors

Sources: Puma Biotechnology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Puma Biotechnology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.